secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001628280-21-021239
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q3 revenue $14.7M (+122% QoQ); net loss $50.3M; LUPKYNIS PSF conversion >68%
--------------------------------------------------------------------------------

- Net revenue $14.7M vs $29K in Q3 2020; net loss $50.3M ($0.39 per share) vs $42.1M loss a year ago.
- Cash and investments $286.4M; 2021 revenue guidance maintained at $40-50M.
- LUPKYNIS PSFs totaled 412 in Q3; cumulative >1,265; conversion rate improved to >68% from 50% in Q2.
- Payer coverage confirmed for 87% of total lives; two preclinical assets AUR200 and AUR300 added.
- AURORA 2 final results expected by end of 2021; Swiss MAA filed; EMA decision anticipated Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828021021239/0001628280-21-021239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828021021239/auph-20211103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-021239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer